title: DNA detection and seroprevalence of human papillomavirus in a cohort of adolescent women.
abstract: OBJECTIVE
  Human papillomavirus (HPV) infections are common in adolescent women, while the rare cancerous sequelae of HPV infections do not generally occur until the 4th or 5th decades of life. This prospective study of a cohort of adolescent women was performed to further our knowledge of the natural history of incident and prevalent HPV infections.
  
  
  METHODS
  Self-vaginal swabs collected from high-risk, unvaccinated adolescent women in a longitudinal study were analysed for HPV DNA. Sera were collected at enrolment and later tested for HPV antibodies. Statistical analysis was performed to determine the HPV genotype distribution and duration of detection, and to determine rates of seropositivity and seroconversion for HPV types represented in the assays.
  
  
  RESULTS
  146 subjects (mean enrolment age=15.4 years; mean duration of follow-up=5.8 years) had samples adequate for analysis of HPV detection, and 95 of these subjects had paired sera available. The cumulative prevalence for high-risk and low-risk HPV types was 95.9% and 91.1%, respectively. HPV types 6, 11, 16 and 18 (HPV types represented in the quadrivalent vaccine) were found at some point in 40.4%, 6.2%, 48% and 24% of participants, respectively. Serological data confirmed exposure to these vaccine-covered types, as well as to other high-risk HPV types.
  
  
  CONCLUSIONS
  In this cohort of adolescent women, high- and low-risk HPV types were frequently detected, and serological data confirmed exposure in most subjects. The high-prevalence HPV types represented in the quadrivalent HPV vaccine further support vaccination of women at an age well before sexual debut.
authors.affiliation: Department of Internal Medicine, Indiana University School of Medicine, , Indianapolis, Indiana, USA.
authors.forename: Aaron C
authors.initials: AC
authors.lastname: Ermel
authors.forename: Marcia L
authors.initials: ML
authors.lastname: Shew
authors.forename: Bree A
authors.initials: BA
authors.lastname: Weaver
authors.forename: Brahim
authors.initials: B
authors.lastname: Qadadri
authors.forename: Cheryl
authors.initials: C
authors.lastname: Denski
authors.forename: Wanzhu
authors.initials: W
authors.lastname: Tu
authors.forename: Yan
authors.initials: Y
authors.lastname: Tong
authors.forename: J D
authors.initials: JD
authors.lastname: Fortenberry
authors.forename: Darron R
authors.initials: DR
authors.lastname: Brown
mesh_terms: D000293:Adolescent; D052685:Alphapapillomavirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D000914:Antibodies, Viral / Q000097:blood*; D015331:Cohort Studies; D004279:DNA, Viral / Q000302:isolation & purification*; D005260:Female; D061809:Human Papillomavirus DNA Tests / Q000379:methods*; D006801:Humans; D008137:Longitudinal Studies; D030361:Papillomavirus Infections / Q000097:blood* / Q000453:epidemiology / Q000276:immunology; D015995:Prevalence; D011446:Prospective Studies; D016036:Seroepidemiologic Studies; D012725:Sexual Behavior; D011795:Surveys and Questionnaires; D014626:Vaginal Smears; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral
keywords: ADOLESCENT; ANTIBODIES; HPV; SEROPREVALENCE
references.citation: Vaccine. 2012 Oct 19;30(47):6686-93
references.pmid: 22959981
references.citation: Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):953-9
references.pmid: 11008914
references.citation: J Clin Microbiol. 2008 Oct;46(10):3437-45
references.pmid: 18716224
references.citation: Am J Obstet Gynecol. 2002 May;186(5):962-8
references.pmid: 12015522
references.citation: Lancet. 2001 Jun 9;357(9271):1831-6
references.pmid: 11410191
references.citation: Arch Pediatr Adolesc Med. 2006 Feb;160(2):151-6
references.pmid: 16461870
references.citation: J Clin Microbiol. 2000 Mar;38(3):1105-12
references.pmid: 10699004
references.citation: J Adolesc Health. 2008 Oct;43(4 Suppl):S5-25, S25.e1-41
references.pmid: 18809145
references.citation: Clin Vaccine Immunol. 2010 May;17(5):818-27
references.pmid: 20237197
references.citation: J Clin Microbiol. 2006 Feb;44(2):366-73
references.pmid: 16455885
references.citation: J Pathol. 1999 Sep;189(1):12-9
references.pmid: 10451482
references.citation: J Clin Microbiol. 2001 Sep;39(9):3092-8
references.pmid: 11526134
references.citation: N Engl J Med. 2003 Feb 6;348(6):518-27
references.pmid: 12571259
references.citation: Arch Pediatr Adolesc Med. 2009 Dec;163(12):1106-11
references.pmid: 19996047
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):699-707
references.pmid: 21173170
references.citation: J Infect Dis. 1996 Nov;174(5):927-36
references.pmid: 8896492
references.citation: Br J Cancer. 2006 Dec 4;95(11):1459-66
references.pmid: 17117182
references.citation: Rev Panam Salud Publica. 2004 Feb;15(2):75-89
references.pmid: 15030652
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):95-100
references.pmid: 11219778
references.citation: J Clin Invest. 2011 Dec;121(12):4593-9
references.pmid: 22133884
references.citation: Virology. 2009 Feb 20;384(2):260-5
references.pmid: 19135222
references.citation: Hum Vaccin. 2011 Feb;7(2):230-8
references.pmid: 21307649
references.citation: Clin Diagn Lab Immunol. 2005 Aug;12(8):959-69
references.pmid: 16085914
references.citation: Clin Diagn Lab Immunol. 2003 Jan;10(1):108-15
references.pmid: 12522048
references.citation: Vaccine. 2012 Nov 20;30 Suppl 5:F24-33
references.pmid: 23199964
references.citation: J Natl Cancer Inst. 2010 Nov 3;102(21):1653-62
references.pmid: 20944077
references.citation: Lancet Oncol. 2005 May;6(5):271-8
references.pmid: 15863374
references.citation: J Infect Dis. 2005 Jan 15;191(2):182-92
references.pmid: 15609227
references.citation: J Infect Dis. 1998 Jun;177(6):1710-4
references.pmid: 9607854
references.citation: J Infect Dis. 2009 Oct 1;200(7):1059-67
references.pmid: 19719390
references.citation: Vaccine. 2006 Mar 30;24 Suppl 1:S16-22
references.pmid: 16219398